semaglutide cardiovascular trial outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice The Big Trial of a
Description
Adjusting the dosage or timing can often help
Researchers exploring microdosing GLP-1 for autoimmune conditions are targeting specifically this anti-inflammatory mechanism
Yes, headaches are a recognized side effect of GLP-1 medications
Whether a licensed provider determines that GLP-1 therapy is clinically appropriate depends on the individual's full medical history, health profile, contraindications, and the provider's independent judgment
As much as 40% of people using these drugs give up after the first month. A second hormone released after eating is glucose-dependent insulinotropic peptide (GIP)
A higher dose of Wegovy (7.2 mg) was approved by the MHRA in January 2026 following the STEP UP trial, which showed: 2 Wegovy 7.2 mg: 20.7% average weight loss Wegovy 2.4 mg: 17.5% average weight loss 50.9% of those on 7.2 mg lost at least 20% of body weight The 7.2 mg dose is not a starting dose
